Table 1 Summary of the different characteristics of the compounds used in this study and their effect on NF-κB. Our previous work on the effects of daunorubicin and etoposide on NF-κB are described in references [7, 8]. * Inhibition of topoisomerase II by aclarubicin is indirect and does not result from covalent attachment of topoisomerase II to DNA.
From: Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
Topo II inhibition | Topo II inhibition induced DNA-damage | DNA intercalation | Generation of oxygen free radicals | Induction of NF-κB DNA-binding | Repression or activation of transcription | |
|---|---|---|---|---|---|---|
Daunorubicin | Yes | Yes | Yes | Yes | Yes | Repression |
Doxorubicin | Yes | Yes | Yes | Yes | Yes | Repression |
Mitoxantrone | Yes | Yes | Yes | No | Yes | Repression |
Aclarubicin | Yes* | No | Yes | Yes | Yes | Repression |
ICRF 193 | Yes | No | No | No | No | No effect |
Etoposide | Yes | Yes | No | No | Yes | Activation |